Simon M Ametamey

List of Publications by Year
in descending order

83 papers	3,120 citations	218381 26 h-index	168136 53 g-index
88 all docs	88 docs citations	88 times ranked	3722 citing authors

#	Article	IF	Citations
1	Rest/stress myocardial perfusion imaging by positron emission tomography with 18F-Flurpiridaz: A feasibility study in mice. Journal of Nuclear Cardiology, 2023, 30, 62-73.	1.4	4
2	In vivo Imaging of Cannabinoid Type 2 Receptors: Functional and Structural Alterations in Mouse Model of Cerebral Ischemia by PET and MRI. Molecular Imaging and Biology, 2022, 24, 700-709.	1.3	11
3	Characterization in nonhuman primates of (R)-[18F]OF-Me-NB1 and (S)-[18F]OF-Me-NB1 for imaging the GluN2B subunits of the NMDA receptor. European Journal of Nuclear Medicine and Molecular Imaging, 2022, , 1.	3.3	8
4	Comparison of three novel radiotracers for GluN2B-containing NMDA receptors in non-human primates: (R)-[¹¹C]NR2B-Me, (R)-[¹⁸F]of-Me-NB1, and (S)-[¹⁸F]of-NB1. Journal of Cerebral Blood Flow and Metabolism, 2022, 42, 1398-1409.	2.4	7
5	Preclinical Development of ¹⁸F-OF-NB1 for Imaging GluN2B-Containing N-Methyl-d-Aspartate Receptors and Its Utility as a Biomarker for Amyotrophic Lateral Sclerosis. Journal of Nuclear Medicine, 2021, 62, 259-265.	2.8	19
6	Identification of a PET Radiotracer for Imaging of the Folate Receptor-Î±: A Potential Tool to Select Patients for Targeted Tumor Therapy. Journal of Nuclear Medicine, 2021, 62, 1475-1481.	2.8	8
7	Prodrug Approach toward the Development of a PET Radioligand for Imaging the GluN2A Subunits of the NMDA Receptor. Organic Letters, 2021, 23, 4584-4587.	2.4	5
8	Positron Emission Tomography Imaging of the Endocannabinoid System: Opportunities and Challenges in Radiotracer Development. Journal of Medicinal Chemistry, 2021, 64, 123-149.	2.9	33
9	First-in-human brain PET imaging of the GluN2B-containing N-methyl-D-aspartate receptor with (R)-11C-Me-NB1. Journal of Nuclear Medicine, 2021, , jnumed.121.262427.	2.8	14
10	Chemoselective ¹⁸F-incorporation into pyridyl acyltrifluoroborates for rapid radiolabelling of peptides and proteins at room temperature. Chemical Communications, 2020, 56, 723-726.	2.2	13
11	N-Methyl-D-Aspartate (NMDA) receptor modulators: a patent review (2015-present). Expert Opinion on Therapeutic Patents, 2020, 30, 743-767.	2.4	33
12	Identification and Preclinical Development of a 2,5,6-Trisubstituted Fluorinated Pyridine Derivative as a Radioligand for the Positron Emission Tomography Imaging of Cannabinoid Type 2 Receptors. Journal of Medicinal Chemistry, 2020, 63, 10287-10306.	2.9	25
13	Evaluation of 5 H â€Thiazolo[3,2â€Î±]pyrimidinâ€5â€ones as Potential GluN2A PET Tracers. ChemMedChem, 2020, 15, 2448-2461.	1.6	2
14	[¹⁸F]Flurpiridaz: Facile and Improved Precursor Synthesis for this Nextâ€Generation Cardiac Positron Emission Tomography Imaging Agent. ChemMedChem, 2020, 15, 1040-1043.	1.6	6
15	Reduced uptake of [11C]â€ABP688, a PET tracer for metabolic glutamate receptor 5 in hippocampus and amygdala in Alzheimerâ€™s dementia. Brain and Behavior, 2020, 10, e01632.	1.0	14
16	Radiation dosimetry of 18F-AzaFol: A first in-human use of a folate receptor PET tracer. EJNMMI Research, 2020, 10, 32.	1.1	23
17	[11C]mHED PET follows a two-tissue compartment model in mouse myocardium with norepinephrine transporter (NET)-dependent uptake, while [18F]LMI1195 uptake is NET-independent. EJNMMI Research, 2020, 10, 114.	1.1	7
18	Neuroimaging with Radiopharmaceuticals Targeting the Glutamatergic System. Chimia, 2020, 74, 960-967.	0.3	5

#	Article	IF	Citations
19	Diastereomerically Pure 6R- and 6S-3â€²-Aza-2â€²-¹⁸F-Fluoro-5-Methyltetrahydrofolates Show Unprecedentedly High Uptake in Folate Receptorâ€“Positive KB Tumors. Journal of Nuclear Medicine, 2019, 60, 135-141.	2.8	8
20	Positron emission tomography of type 2 cannabinoid receptors for detecting inflammation in the central nervous system. Acta Pharmacologica Sinica, 2019, 40, 351-357.	2.8	39
21	Identification and Preclinical Evaluation of a Radiofluorinated Benzazepine Derivative for Imaging the GluN2B Subunit of the Ionotropic NMDA Receptor. Journal of Nuclear Medicine, 2019, 60, 259-266.	2.8	26
22	Synthesis and Structureâ€“Affinity Relationship of Small Molecules for Imaging Human CD80 by Positron Emission Tomography. Journal of Medicinal Chemistry, 2019, 62, 8090-8100.	2.9	7
23	Dynamic changes in cerebral and peripheral markers of glutamatergic signaling across the human sleepâ€“wake cycle. Sleep, 2019, 42, .	0.6	20
24	Structureâ€“Affinity Relationships of 2,3,4,5-Tetrahydro-1H-3-benzazepine and 6,7,8,9-Tetrahydro-5H-benzo[7]annulen-7-amine Analogues and the Discovery of a Radiofluorinated 2,3,4,5-Tetrahydro-1H-3-benzazepine Congener for Imaging GluN2B Subunit-Containing N-Methyl-d-aspartate Receptors. Journal of Medicinal Chemistry, 2019, 62, 9450-9470.	2.9	26
25	Radiation dosimetry of [18F]-PSS232â€”a PET radioligand for imaging mGlu5 receptors in humans. EJNMMI Research, 2019, 9, 56.	1.1	2
26	Preclinical Evaluation of Benzazepine-Based PET Radioligands (R)- and (S)-¹¹C-Me-NB1 Reveals Distinct Enantiomeric Binding Patterns and a Tightrope Walk Between GluN2B- and Ïƒ₁-Receptorâ€“Targeted PET Imaging. Journal of Nuclear Medicine, 2019, 60, 1167-1173.	2.8	30
27	Recent progress in allosteric modulators for GluN2A subunit and development of GluN2Aâ€selective nuclear imaging probes. Journal of Labelled Compounds and Radiopharmaceuticals, 2019, 62, 552-560.	0.5	7
28	Modification of the 4-phenylbutyl side chain of potent 3-benzazepine-based GluN2B receptor antagonists. Bioorganic and Medicinal Chemistry, 2019, 27, 3559-3567.	1.4	4
29	Tetrahydro-3-benzazepines with fluorinated side chains as NMDA and Ïƒ1 receptor antagonists: Synthesis, receptor affinity, selectivity and antiallodynic activity. European Journal of Medicinal Chemistry, 2019, 177, 47-62.	2.6	7
30	Pharmacokinetic properties of enantiomerically pure GluN2B selective NMDA receptor antagonists with 3-benzazepine scaffold. Journal of Pharmaceutical and Biomedical Analysis, 2019, 172, 214-222.	1.4	15
31	Synthesis and pharmacological evaluation of fluorinated benzo[7]annulenâ€7â€amines as GluN2Bâ€selective NMDA receptor antagonists. Journal of Labelled Compounds and Radiopharmaceuticals, 2019, 62, 354-379.	0.5	8
32	Structureâ€“Activity Relationship Studies of Pyridine-Based Ligands and Identification of a Fluorinated Derivative for Positron Emission Tomography Imaging of Cannabinoid Type 2 Receptors. Journal of Medicinal Chemistry, 2019, 62, 11165-11181.	2.9	19
33	Metabotropic glutamate receptor subtype 5 is altered in LPS-induced murine neuroinflammation model and in the brains of AD and ALS patients. European Journal of Nuclear Medicine and Molecular Imaging, 2019, 46, 407-420.	3.3	24
34	Fluorinated GluN2B Receptor Antagonists with a 3â€Benzazepine Scaffold Designed for PET Studies. ChemMedChem, 2018, 13, 1058-1068.	1.6	13
35	Reduced 18F-Folate Conjugates as a New Class of PET Tracers for Folate Receptor Imaging. Bioconjugate Chemistry, 2018, 29, 1119-1130.	1.8	10
36	Evaluation of 4-oxo-quinoline-based CB2 PET radioligands in R6/2 chorea huntington mouse model and human ALS spinal cord tissue. European Journal of Medicinal Chemistry, 2018, 145, 746-759.	2.6	28

#	Article	IF	Citations
37	Automated cGMPâ€compliant radiosynthesis of [¹⁸F]â€(E)â€PSS232 for brain PET imaging of metabotropic glutamate receptor subtype 5. Journal of Labelled Compounds and Radiopharmaceuticals, 2018, 61, 30-37.	0.5	2
38	Evaluation of ¹¹C-Me-NB1 as a Potential PET Radioligand for Measuring GluN2B-Containing NMDA Receptors, Drug Occupancy, and Receptor Cross Talk. Journal of Nuclear Medicine, 2018, 59, 698-703.	2.8	46
39	A first-in-man PET study of [18F]PSS232, a fluorinated ABP688 derivative for imaging metabotropic glutamate receptor subtype 5. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1041-1051.	3.3	16
40	Radioligands for positron emission tomography imaging of cannabinoid type 2 receptor. Journal of Labelled Compounds and Radiopharmaceuticals, 2018, 61, 299-308.	0.5	35
41	Replacement of the Benzylpiperidine Moiety with Fluorinated Phenylalkyl Side Chains for the Development of GluN2B Receptor Ligands. ChemMedChem, 2018, 13, 2522-2529.	1.6	6
42	Ketamine and Ceftriaxone-Induced Alterations in Glutamate Levels Do Not Impact the Specific Binding of Metabotropic Glutamate Receptor Subtype 5 Radioligand [18F]PSS232 in the Rat Brain. Pharmaceuticals, 2018, 11, 83.	1.7	4
43	Improved Syntheses of the mGlu5 Antagonists MMPEP and MTEP Using Sonogashira Cross-Coupling. Pharmaceuticals, 2018, 11, 24.	1.7	0
44	Synthesis and Pharmacological Evaluation of Enantiomerically Pure GluN2B Selective NMDA Receptor Antagonists. ChemMedChem, 2018, 13, 1580-1587.	1.6	21
45	Unexpected reactivity of cyclic perfluorinated iodanes with electrophiles. Chemical Communications, 2018, 54, 8999-9002.	2.2	3
46	Radiosynthesis and evaluation of an 18Fâ€“labeled silicon containing exendin-4 peptide as a PET probe for imaging insulinoma. EJNMMI Radiopharmacy and Chemistry, 2018, 3, 1.	1.8	11
47	Cannabinoid receptor type 2 (CB2) as one of the candidate genes in human carotid plaque imaging: Evaluation of the novel radiotracer [11 C]RS-016 targeting CB2 in atherosclerosis. Nuclear Medicine and Biology, 2017, 47, 31-43.	0.3	26
48	Synthesis and Biological Evaluation of Quinoxaline Derivatives for <scp>PET</scp> Imaging of the <scp>NMDA</scp> Receptor. Helvetica Chimica Acta, 2017, 100, e1700204.	1.0	3
49	Imaging the glutamate receptor subtypesâ€”Much achieved, and still much to do. Drug Discovery Today: Technologies, 2017, 25, 27-36.	4.0	13
50	CD80 Is Upregulated in a Mouse Model with Shear Stress-Induced Atherosclerosis and Allows for Evaluating CD80-Targeting PET Tracers. Molecular Imaging and Biology, 2017, 19, 90-99.	1.3	19
51	Novel chemoselective ¹⁸F-radiolabeling of thiol-containing biomolecules under mild aqueous conditions. Chemical Communications, 2016, 52, 6083-6086.	2.2	35
52	⁶⁴Cu- and ⁶⁸Ga-Based PET Imaging of Folate Receptor-Positive Tumors: Development and Evaluation of an Albumin-Binding NODAGAâ€“Folate. Molecular Pharmaceutics, 2016, 13, 1979-1987.	2.3	41
53	Discovery of a fluorinated 4â€oxoâ€quinoline derivative as a potential positron emission tomography radiotracer for imaging cannabinoid receptor type 2. Journal of Neurochemistry, 2016, 138, 874-886.	2.1	31
54	Noninvasive PET Imaging and Tracking of Engineered Human Muscle Precursor Cells for Skeletal Muscle Tissue Engineering. Journal of Nuclear Medicine, 2016, 57, 1467-1473.	2.8	12

#	Article	IF	Citations
55	Comparative Studies of Three Pairs of Î±- and Î³-Conjugated Folic Acid Derivatives Labeled with Fluorine-18. Bioconjugate Chemistry, 2016, 27, 74-86.	1.8	24
56	Evaluation of the Radiolabeled Boronic Acid-Based FAP Inhibitor MIP-1232 for Atherosclerotic Plaque Imaging. Molecules, 2015, 20, 2081-2099.	1.7	37
57	Synthesis, radiolabeling and evaluation of novel 4-oxo-quinoline derivatives as PET tracers for imaging cannabinoid type 2 receptor. European Journal of Medicinal Chemistry, 2015, 92, 554-564.	2.6	56
58	Investigation of the chick embryo as a potential alternative to the mouse for evaluation of radiopharmaceuticals. Nuclear Medicine and Biology, 2015, 42, 226-233.	0.3	25
59	Preclinical evaluation and testâ€“retest studies of [18F]PSS232, a novel radioligand for targeting metabotropic glutamate receptor 5 (mGlu5). European Journal of Nuclear Medicine and Molecular Imaging, 2015, 42, 128-137.	3.3	27
60	Regional cerebral blood flow estimated by early PiB uptake is reduced in mild cognitive impairment and associated with age in an amyloid-dependent manner. Neurobiology of Aging, 2015, 36, 1619-1628.	1.5	41
61	Discovery of a High Affinity and Selective Pyridine Analog as a Potential Positron Emission Tomography Imaging Agent for Cannabinoid Type 2 Receptor. Journal of Medicinal Chemistry, 2015, 58, 4266-4277.	2.9	55
62	Quantitative positron emission tomography of <scp>mG</scp>luR5 in rat brain with [¹⁸F]PSS232 at minimal invasiveness and reduced model complexity. Journal of Neurochemistry, 2015, 133, 330-342.	2.1	23
63	Development and Evaluation of Novel PET Tracers for Imaging Cannabinoid Receptor Type 2 in Brain. Chimia, 2014, 68, 208.	0.3	8
64	In Vitro and In Vivo Evaluation of Nâ€{2â€[4â€(3â€Cyanopyridinâ€2â€yl)piperazinâ€1â€yl]ethyl}â€3â€[¹¹C]methoxybenzÂamide, a Positron Emission Tomography (PET) Radioligand for Dopamine D₄ Receptors, in Rodents. Chemistry and Biodiversity, 2014, 11, 1298-1308.	1.0	4
65	Synthesis and Preliminary Evaluation of a 2-Oxoquinoline Carboxylic Acid Derivative for PET Imaging the Cannabinoid Type 2 Receptor. Pharmaceuticals, 2014, 7, 339-352.	1.7	17
66	Towards non-invasive imaging of vulnerable atherosclerotic plaques by targeting co-stimulatory molecules. International Journal of Cardiology, 2014, 174, 503-515.	0.8	32
67	Radiolabeling and in vitro /in vivo evaluation of Nâ€(1â€adamantyl)â€8â€methoxyâ€4â€oxoâ€1â€phenylâ€1,4â€dihydroquinolineâ€3â€carboxamide as a <scp>PET</scp> probe for imaging cannabinoid type 2 receptor. Journal of Neurochemistry, 2013, 126, 616-624.	3.3	43
68	Synthesis and in vitro/in vivo pharmacological evaluation of [11C]-ThioABP, a novel radiotracer for imaging mGluR5 with PET. MedChemComm, 2013, 4, 520.	3.5	3
69	Radiosynthesis and Preclinical Evaluation of 3â€²-Aza-2â€²-[¹⁸F]fluorofolic Acid: A Novel PET Radiotracer for Folate Receptor Targeting. Bioconjugate Chemistry, 2013, 24, 205-214.	1.8	43
70	Synthesis and biological evaluation of 18F-labeled fluoropropyl tryptophan analogs as potential PET probes for tumor imaging. European Journal of Medicinal Chemistry, 2013, 70, 768-780.	2.6	30
71	Synthesis and In Vitro Evaluation of E- and Z-Geometrical Isomers of PSS232 as Potential Metabotropic Glutamate Receptors Subtype 5 (mGlu5) Binders. Synthesis, 2013, 45, 1877-1885.	1.2	8
72	¹⁸Fâ€Radiolabeling of Aromatic Compounds Using Triarylsulfonium Salts. European Journal of Organic Chemistry, 2012, 2012, 889-892.	1.2	77

#	Article	IF	Citations
73	In vitro and in vivo evaluation of [18F]-FDEGPECO as a PET tracer for imaging the metabotropic glutamate receptor subtype 5 (mGluR5). NeuroImage, 2011, 56, 984-991.	2.1	16
74	Structureâ^'Activity Relationships of Fluorinated (E)-3-((6-Methylpyridin-2-yl)ethynyl)cyclohex-2-enone-O-methyloxime (ABP688) Derivatives and the Discovery of a High Affinity Analogue as a Potential Candidate for Imaging Metabotropic Glutamate Recepors Subtype 5 (mGluR5) with Positron Emission Tomography (PET). Journal of Medicinal Chemistry, 2010, 53, 4009-4017.	2.9	22
75	Organofluorosilanes as Model Compounds for ¹⁸Fâ€Labeled Siliconâ€Based PET Tracers and their Hydrolytic Stability: Experimental Data and Theoretical Calculations (PET=Positron Emission) Tj ETQq1 1 0.784314 rgBT /Overloc	4.7	40
76	Nucleophilic ring-opening of activated aziridines: A one-step method for labeling biomolecules with fluorine-18. Journal of Fluorine Chemistry, 2009, 130, 902-912.	0.9	38
77	Siliconâ€Based Building Blocks for Oneâ€Step ¹⁸Fâ€Radiolabeling of Peptides for PET Imaging. Angewandte Chemie - International Edition, 2008, 47, 4922-4925.	7.2	103
78	Fluorine-18 Click Radiosynthesis and Preclinical Evaluation of a New ¹⁸F-Labeled Folic Acid Derivative. Bioconjugate Chemistry, 2008, 19, 2462-2470.	1.8	76
79	Molecular Imaging with PET. Chemical Reviews, 2008, 108, 1501-1516.	23.0	1,074
80	Human PET studies of metabotropic glutamate receptor subtype 5 with 11C-ABP688. Journal of Nuclear Medicine, 2007, 48, 247-52.	2.8	121
81	Synthesis and Characterization of a C(6) Nucleoside Analogue for thein vivo Imaging of the Gene Expression ofHerpes Simplex Virus Type-1 Thymidine Kinase (HSV1 TK). Chemistry and Biodiversity, 2006, 3, 274-283.	1.0	18
82	Radiosynthesis and preclinical evaluation of 11C-ABP688 as a probe for imaging the metabotropic glutamate receptor subtype 5. Journal of Nuclear Medicine, 2006, 47, 698-705.	2.8	132
83	Synthesis and preclinical evaluation of a folic acid derivative labeled with 18F for PET imaging of folate receptor-positive tumors. Journal of Nuclear Medicine, 2006, 47, 1153-60.	2.8	60